Clinical trial

Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

NCT04443348

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2020-12-16

PhasePHASE2

Study timeline

Study start (actual)2020-12-16Date precision: day

Registry last updated2026-07-13

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Triple Negative Breast Cancerunresolved

Hormone Receptor Positive (HR+), HER2-negative Breast Cancerunresolved

Biopsy-proven, Positive Lymph Node(s)unresolved

Interventions

Radiation Therapy BoostRADIATION

PembrolizumabDRUG · verified · RxNorm: pembrolizumab

PaclitaxelDRUG · verified · RxNorm: paclitaxel

CarboplatinDRUG · verified · RxNorm: carboplatin

CyclophosphamideDRUG · verified · RxNorm: cyclophosphamide

DoxorubicinDRUG · verified · RxNorm: doxorubicin

CapecitabineDRUG · verified · RxNorm: capecitabine

Sponsors & collaborators

Laura M. Spring, MDlead sponsor

Merck Sharp & Dohme LLCcollaborator

Breast Cancer Research Foundationcollaborator

Translational Breast Cancer Research Consortiumcollaborator

Mapped research locations

BostonMassachusetts, United States2 New YorkNew York, United States1 HoustonTexas, United States1 BaltimoreMaryland, United States1 DurhamNorth Carolina, United States1 Washington D.C.District of Columbia, United States1 RochesterMinnesota, United States1 Chapel HillNorth Carolina, United States1 The BronxNew York, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04443348 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.